Friedlaender, A. .; Metro, G. .; Signorelli, D. .; Gili, A. .; Economopoulou, P. .; Roila, F. .; Banna, G. .; De Toma, A. .; Camerini, A. .; Christopoulou, A. . Impact of Performance Status on Non-Small-Cell Lung Cancer Patients With a PD-L1 Tumour Proportion Score ≥50% Treated With Front-Line Pembrolizumab. AO 2020, 59, 1058-1063.